About the 2026 Program 

This comprehensive, multi-session program delivers a deep, practice-focused exploration of interventional oncology (IO) across HCC and emerging disease areas, emphasizing multidisciplinary collaboration and real-world clinical application. Sessions begin with a strategic examination of multidisciplinary decision-making in HCC, focusing on how systemic and locoregional therapies can be optimally integrated to individualize patient care. 

Then, attendees will explore why combination therapies may fail in HCC, translating scientific insights into future therapeutic directions. Additional sessions address optimizing multidisciplinary care for transplant-eligible patients and examine downstaging strategies to curative intent through interactive, case-based discussions grounded in real-world clinical scenarios. 

This year's agenda expands to include intratumoral therapies in immuno-oncology, highlighting mechanisms of action, delivery techniques, and clinical integration, alongside practical reviews of current HCC clinical trials and evolving guidelines. Evidence-based updates for non-HCC malignancies ensure relevance across disease states, while hands-on, case-based discussions in Y90 therapy, a forward-looking exploration of novel technologies, and a culminating focus on personalized and precision approaches reinforce the program’s commitment to actionable, practice-changing education. 

Times and complete faculty information coming soon! 

Session	Title and Focus
Day One Attendee Check-In and Breakfast
Session 1	Multidisciplinary Decision-Making in HCC: Integrating Systemic and Locoregional Therapies Moderator (IR): Beau Toskich, MD, FSIR Moderator (MDP): Adam Burgoyne, MD, PhD Systemic Therapy for Earlier Staged Disease: Who, When and Why: Adam Burgoyne, MD, PhD Local Therapy as an Adjuvant to Systemic Therapy: Balancing Abscopal With the Unknown: Lindsay Thornton, MD Local Therapy as a Salvage to Systemic Therapy: Jordan Tasse, MD Treatment Strategies in HCC: When Does Combining Therapies Improve Outcomes?: Christopher D. Malone, MD  Case-Based Discussion: Optimizing Therapy Combinations (TB): Coming Soon
Session 2	When Combination Therapies Fail in HCC: Scientific Insights and Future Directions (presented in collaboration with SITC) Moderator (IR): Terence P. Gade, MD, PhD Moderator (MDP): Coming Soon Molecular Drivers of Resistance in HCC: Coming Soon Tumor Microenvironment and Immune Evasion: Lucianne Kagohara, PhD Still Unanswered Trial Questions: Coming Soon Strategies to Overcome Resistance: Emerging Therapies: James Zhe Hui, MD, PhD  Panel Discussion
Session 3	Optimizing Multidisciplinary Care in the Transplant Patient (presented in collaboration with AASLD) Moderator (IR): SIO Moderator (MDP): Coming Soon Patient Selection in the Immunotherapy Era: A Hepatology Framework: Coming Soon Etiology Matters: Metabolic, Viral, and Alcohol-Related HCC and Transplant Implications: Coming Soon What the Explant Teaches Us: A Transplant Surgeon’s Perspective: Coming Soon Optimizing Locoregional Therapy in the Transplant Candidate: Beau Toskich, MD, FSIR Discussion
	Lunch
Session 4	Downstaging to Curative Intent With Case-Based Discussions Moderator (IR): Coming Soon Moderator (MDP): Coming Soon Locoregional Strategies for Downstaging Advanced and Intermediate HCC: Robert J. Lewandowski, MD, FSIR  Radiation Therapy for HCC: Targeting and Dose Optimization: Garrett Green, MD Expanding Indications for Transplantation: What the Future Looks Like: Coming Soon Who Can be Safely Downstaged: Hepatology Perspective (AASLD): Coming Soon Case-Based Discussion: Defining and Downstaging to Curative Intent: Coming Soon
Session 5	Intratumoral Therapies in IO: Mechanisms, Delivery, and Clinical Integration (presented in collaboration with SITC) Moderator (IR): Coming Soon Moderator (MDP): Coming Soon Intratumoral Immunotherapy: Mechanisms and Early Data: Coming Soon Novel Agents for Direct Tumor Injection: Coming Soon Minimal Residual Disease and ctDNA: Coming Soon Logistics & Tips for Effective Delivery: Rony Avritscher, MD, FSIR Discussion
Session 6	Interventional Oncology in Practice: Current HCC Trials and Evolving Guidelines (presented in collaboration with AASLD) Moderator (IR): Coming Soon Moderator (MDP): Amit Singal, MD HCC Trial Data Update: What's New Since 2025? Kirema Garcia-Reyes Guideline Interpretation in HCC: What They Say and What They Leave Out: Riad Salem, MD, MBA Why Good Ideas Fail: Lessons from Trial Design and Execution: Christopher D. Malone, MD Applying HCC Trial Data to Daily Practice: Amit Singal, MD Discussion
	Attendee & Faculty Reception
Day Two Attendee Check-In and Breakfast
Session 7	Evidence-Based Updates and Guidelines for Non-HCC Malignancies Moderator (IR): Bruno Odisio, MD, PhD, FSIR Moderator (MDP): Milind Javle, MD Interventional Oncology Beyond HCC: Evidence, Indications, and Opportunity: Christopher D. Malone, MD Data Updates in Non-HCC Malignancies (new since 2025): Milind Javle, MD Guidelines Across Disease Sites: What They Mean for IO Practice: Lindsay Thornton, MD Novel Endpoints and Metrics in IO Trials: Beau Toskich, MD, FSIR Discussion
Session 8	Practical Y90 Case-Based Discussion Moderator (IR): Kirema Garcia-Reyes, MD Moderator (MDP): Coming Soon Managing High Lung Shunts: William S. Rilling, MD, FSIR  Macrovascular Invasion: Edward Kim, MD, FSIR Large Tumors: Hyo-Cheol Kim, MD Multifocal Disease: Ammar Sarwar, MD, FSIR
Session 9	Novel Technologies Session (Disease Agnostic) Moderator (IR): Rony Avritscher, MD Moderator (MDP): Coming Soon AI and Image-Guided Navigation Tools: Julius Chapiro, MD, PhD Robotics and Advanced Catheter Systems: Coming Soon Next-Generation Ablation and Embolic Devices: Jordan Tasse, MD Emerging Imaging Modalities for Procedural Planning: Bruno Odisio, MD, PhD, FSIR, FCIRSE Discussion
	Lunch
Session 10	Personalized and Precision Approaches in Interventional Oncology Moderator (IR): Julius Chapiro, MD, PhD Moderator (MDP): Tullia Bruno, PhD Biomarker-Guided Patient Selection for Interventional Oncology Procedures: Tullia Bruno, PhD Precision Ablation and Targeted Local Therapy: Martijn Meijerink, MD, PhD Integrating AI Into Multidisciplinary Decision-Making: Julius Chapiro, MD, PhD Future of Personalized IO: Integrating Genomics and AI: Terence P. Gade, MD, FSIR

 

The Society of Interventional Oncology’s Next Summit: Novel Explorations in Combination Therapies is provided in collaboration with the Society for Immunotherapy of Cancer and the American Association for the Study of Liver Disease.